New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:37 EDTPRGOPerrigo near-term outlook has improved, says RBC Capital
RBC Capital expects Perrigo to benefit from several positive catalysts, including lower buyside expectations, tailwinds for the company's consumer health business, and increased focus on its Tysabri SPMS opportunity. The firm keeps a $160 price target and Outperform rating on the shares.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
08:08 EDTPRGOGalmed and Perrigo sign agreement for aramchol API production
Galmed (GLMD) has entered into a Manufacturing Services Agreement with Perrigo (PRGO) subsidiary Perrigo API Ltd. for the large-scale production of the active pharmaceutical ingredient of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.
January 20, 2015
11:16 EDTPRGOPerrigo management to meet with B. Riley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use